The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates

The global burden of disease caused by respiratory syncytial virus (RSV) is increasingly recognised, not only in infants, but also in older adults (aged ≥65 years). Advances in knowledge of the structural biology of the RSV surface fusion glycoprotein have revolutionised RSV vaccine development by p...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Lancet infectious diseases Jg. 18; H. 10; S. e295 - e311
Hauptverfasser: Mazur, Natalie I, Higgins, Deborah, Nunes, Marta C, Melero, José A, Langedijk, Annefleur C, Horsley, Nicole, Buchholz, Ursula J, Openshaw, Peter J, McLellan, Jason S, Englund, Janet A, Mejias, Asuncion, Karron, Ruth A, Simões, Eric AF, Knezevic, Ivana, Ramilo, Octavio, Piedra, Pedro A, Chu, Helen Y, Falsey, Ann R, Nair, Harish, Kragten-Tabatabaie, Leyla, Greenough, Anne, Baraldi, Eugenio, Papadopoulos, Nikolaos G, Vekemans, Johan, Polack, Fernando P, Powell, Mair, Satav, Ashish, Walsh, Edward E, Stein, Renato T, Graham, Barney S, Bont, Louis J
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States Elsevier Ltd 01.10.2018
Elsevier B.V
Elsevier Limited
Schlagworte:
Adults
Antibodies, Monoclonal - immunology
Antibodies, Viral - immunology
Antigens
Candidates
Children
Clinical trials
COVID-19 vaccines
Disease prevention
Global Health
Glycoproteins
Humans
Immunoglobulins
Immunology
Infants
Infections
Infectious diseases
Medical research
Monoclonal antibodies
Mutation
Nanoparticles
Older people
Proteins
Respiratory syncytial virus
Respiratory Syncytial Virus Infections - prevention & control
Respiratory Syncytial Virus Vaccines - immunology
Vaccine development
Vaccines
Viruses
World Health Organization
United States > US
ISSN:1473-3099, 1474-4457, 1474-4457
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The global burden of disease caused by respiratory syncytial virus (RSV) is increasingly recognised, not only in infants, but also in older adults (aged ≥65 years). Advances in knowledge of the structural biology of the RSV surface fusion glycoprotein have revolutionised RSV vaccine development by providing a new target for preventive interventions. The RSV vaccine landscape has rapidly expanded to include 19 vaccine candidates and monoclonal antibodies (mAbs) in clinical trials, reflecting the urgency of reducing this global health problem and hence the prioritisation of RSV vaccine development. The candidates include mAbs and vaccines using four approaches: (1) particle-based, (2) live-attenuated or chimeric, (3) subunit, (4) vector-based. Late-phase RSV vaccine trial failures highlight gaps in knowledge regarding immunological protection and provide lessons for future development. In this Review, we highlight promising new approaches for RSV vaccine design and provide a comprehensive overview of RSV vaccine candidates and mAbs in clinical development to prevent one of the most common and severe infectious diseases in young children and older adults worldwide.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:1473-3099
1474-4457
1474-4457
DOI:10.1016/S1473-3099(18)30292-5